Assessment of clinical and economic impact  of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States

CONCLUSIONS: Rivaroxaban + aspirin was found to provide positive net clinical benefit on the annual number of MACE/MALE avoided, with a modest increase in the PMPM cost.PMID:38044632 | DOI:10.1080/13696998.2023.2290386

Source: Journal of Medical Economics - December 4, 2023 Category: Health Management Authors: Anshul Shah Firas Dabbous Surbhi Shah Veronica Ashton Akshay Kharat Source Type: research